President Donald Trump announced Thursday a new initiative called "TrumpRx" aimed at lowering the cost of popular weight-loss drugs Wegovy and Zepbound, in deals with pharmaceutical companies Novo Nordisk and Eli Lilly.
The program seeks to make these treatments more affordable for millions of Americans struggling with obesity.
Under the agreement, Novo Nordisk will offer the lowest doses of Wegovy for $149 per month, while Eli Lilly's Zepbound will start at $299 for self-pay patients, dropping to $50 for Medicare beneficiaries, FoxBusiness reported.
Other Lilly drugs, including Orforglipron, Emgality, Trulicity, and Mounjaro, will also see price cuts of 50% to 60% for direct-to-consumer purchases through the company's LillyDirect platform.
Trump called the announcement "a triumph for American patients that will save lives and improve the health of millions and millions of Americans."
He emphasized that the program will extend coverage under Medicare and Medicaid, allowing eligible patients to access GLP-1 weight-loss drugs more easily.
GLP-1 medications, originally developed to treat type 2 diabetes, work by mimicking natural hormones to control appetite, increase feelings of fullness, and improve blood sugar management.
@ewarren @BernieSanders are pissed off! Instead of Big Pharma supplying Millions to @DNC campaigns to keep prices high, Trump got them to lower their prices and MAHA. https://t.co/JJoCxR8NNx
— George Palmer (@gfp3) November 6, 2025
Wegovy, Zepbound Costs to Start at $350 Under TrumpRx
Drugs such as Wegovy and Zepbound have become highly sought after for obesity treatment, but high prices and limited insurance coverage have made them difficult for many patients to obtain.
The TrumpRx initiative is designed to address these barriers. Novo Nordisk has already launched its direct-to-patient platform, NovoCarePharmacy, while Lilly's LillyDirect allows patients to buy Zepbound and Mounjaro without going through insurance.
Both companies said they are reviewing US pricing across Medicare, Medicaid, and self-pay channels.
Experts note that some details of the program remain unclear. Art Caplan, head of the Division of Medical Ethics at NYU Langone Medical Center, said, "The price reduction is important, and the manufacturers seem willing, but they're still very expensive."
Questions remain about how the plan will affect patients who rely on Medicare coverage for weight loss alone, which is currently prohibited.
According to NBC News, senior administration officials said that under TrumpRx, monthly costs for Wegovy and Zepbound will start at $350 and drop to $250 over the next two years.
Coverage for patients on Medicare and Medicaid will be available for those who are overweight or obese with certain conditions, such as heart disease, kidney disease, or severe obesity.
Join the Conversation